2024年11月11日,荣昌生物(09995.HK)股票在港交所盘中出现大涨行情,股价一度大涨5.26%,引起市场广泛关注。
据相关利好消息披露,荣昌生物发布2024年第三季度业绩数据,营业收入同比增长57.1%,达到4.67亿元人民币,表现符合市场预期。公司核心产品泰它西普和维迪西妥单抗在自身免疫疾病和肿瘤领域均实现持续放量,临床研发和商业化推广工作进展顺利。此外,其他创新药物如RC18、RC88也有多项临床试验成果不断释放,适应症范围不断扩大,产品管线持续丰富。
分析人士认为,此次公司业绩增长出色,推动市场重新认识公司的产品力和发展前景,从而引发股价大涨。总体来看,随着核心产品市场份额不断扩大,以及丰富的创新药物管线持续推进,公司长期发展动能强劲,投资价值备受看好。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.